FDA Kicks Off 510(k) Reform Plan, Punts Some Decisions To IOM

FDA’s plan for improving its 510(k) pre-market submission program includes clarifying instances where clinical data should be included and streamlining its “de novo” review process for certain innovative, lower-risk devices.